

## Special Issue

# Bioactive Nucleosides and Nucleotides

### Message from the Guest Editor

Analogues of nucleosides and nucleotides have had a tremendous impact, not only as (bio)chemical tools, but particularly also as drugs for human therapy. Nucleoside and nucleotide derivatives are currently widely used to treat cancer and viral infections, with the introduction of the highly potent anti-HCV drug Sofosbuvir (a nucleotide prodrug) representing the most recent milestone. However, nucleosides also find increasing interest as antibacterial drug candidates, which are urgently needed in the context of emerging resistances against established antibiotics. For this Special Issue, we welcome contributions from all fields of nucleoside and nucleotide chemistry, may they be related to fundamental science or potential pharmaceutical applications. This also includes work that is mainly or even exclusively focused on organic synthesis. The synthetic preparation of nucleoside and nucleotide analogues is not trivial, and I strongly feel that there is an unfortunate tendency to overlook this highly important part of our daily work as chemists. Prof. Dr. Christian Ducho

---

### Guest Editor

Prof. Dr. Christian Ducho

Department of Pharmacy, Pharmaceutical and Medicinal Chemistry,  
Saarland University, Campus C2 3, 66 123 Saarbrücken, Germany

---

### Deadline for manuscript submissions

closed (31 December 2018)



## Molecules

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.6  
Indexed in PubMed



[mdpi.com/si/12400](https://mdpi.com/si/12400)

*Molecules*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[molecules@mdpi.com](mailto:molecules@mdpi.com)

[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)





# Molecules

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.6  
Indexed in PubMed



[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)



## About the Journal

### Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

---

### Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

#### Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).